Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Nov 11:2023:6628492.
doi: 10.1155/2023/6628492. eCollection 2023.

Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature

Carlee Blakemore  1 , Sudarshawn Damodharan  1   2 , Diane Puccetti  1   2
Affiliations
Case Reports

Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature

Carlee Blakemore et al. Case Rep Oncol Med. .

Abstract

Acute myeloid leukemia (AML) with the high-risk variant inv(3)/t(3;3) or t(3;3)(q21;26.2) is rarely seen in the pediatric and young adult population. It is associated with poor outcomes with ineffective therapeutic options. Here, we present a case of an 18-year-old female with treatment refractory inv(3) AML in whom remission was unable to be obtained. Better treatment options are needed given the increased resistance to traditional therapy this subtype portrays. Here, we review the literature on pediatric and young adult inv(3) AML along with newer therapeutic options.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Gamis A. S., Alonzo T. A., Perentesis J. P., Meshinchi S., on behalf of the COG Acute Myeloid Leukemia Committee Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. Pediatric Blood & Cancer . 2013;60(6):964–971. doi: 10.1002/pbc.24432. - DOI - PMC - PubMed
    1. Rubnitz J. E., Kaspers G. J. L. How I treat pediatric acute myeloid leukemia. Blood . 2021;138(12):1009–1018. doi: 10.1182/blood.2021011694. - DOI - PubMed
    1. Sun J., Konoplev S. N., Wang X., et al. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology, Inc . 2011;24(3):384–389. doi: 10.1038/modpathol.2010.210. - DOI - PubMed
    1. Sitges M., Boluda B., Garrido A., et al. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3; q26.2): study of 61 patients treated with intensive protocols. European Journal of Haematology . 2020;105(2):138–147. doi: 10.1111/ejh.13417. - DOI - PubMed
    1. Rogers H. J., Vardiman J. W., Anastasi J., et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21; q26.2): a Bone Marrow Pathology Group study. Haematologica . 2014;99(5):821–829. doi: 10.3324/haematol.2013.096420. - DOI - PMC - PubMed

Publication types

LinkOut - more resources